Seattle Genetics, Inc. (NASDAQ:SGEN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07. Submission of Matters to a Vote of Security Holders.
At the 2017 Annual Meeting of Stockholders (the Annual Meeting)
of Seattle Genetics, Inc. (the Company) held on May19, 2017, the
Companys stockholders voted on the four proposals listed
below.The final results of the votes regarding each proposal are
set forth below.The proposals are described in detail in the
Companys definitive proxy statement for the Annual Meeting filed
with the Securities and Exchange Commission on April5, 2017 (the
Proxy Statement).
| 1. |
To elect the following two ClassI directors to hold office until the Companys 2020 Annual Meeting of Stockholders. |
|
Name |
Votes For | Votes Withheld | Broker Non-Votes | |||||||||
|
David W. Gryska |
123,796,278 | 1,083,624 | 9,728,782 | |||||||||
|
John A. Orwin |
124,370,870 | 509,032 | 9,728,782 |
| 2. |
To ratify the appointment of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017. |
| Votes For | VotesAgainst | Abstentions | Broker Non-Votes | |||||||||||
| 133,524,539 | 934,942 | 149,203 |
| 3. |
To approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the Proxy Statement. |
| Votes For | VotesAgainst | Abstentions | Broker Non-Votes | |||||||||||
| 122,684,286 | 1,369,162 | 826,454 | 9,728,782 |
| 4. |
To indicate, on an advisory basis, the preferred frequency of an advisory vote on the compensation of the Companys named executive officers (the Frequency Proposal). |
| Votes | ||||
|
One Year |
119,473,297 | |||
|
Two Years |
128,803 | |||
|
Three Years |
5,102,246 | |||
|
Abstentions |
175,556 | |||
|
Broker Non-Votes |
9,728,782 |
Based on the Board of Directors recommendation in the Proxy
Statement, the voting results on the Frequency Proposal and its
consideration of the appropriate voting frequency for the Company
at this time, the Companys Board of Directors determined that the
Company will hold an annual advisory vote on the compensation of
the Companys named executive officers.
About Seattle Genetics, Inc. (NASDAQ:SGEN)
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company’s pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer. Seattle Genetics, Inc. (NASDAQ:SGEN) Recent Trading Information
Seattle Genetics, Inc. (NASDAQ:SGEN) closed its last trading session up +0.78 at 67.45 with 358,717 shares trading hands.
